Discussion
The results presented demonstrate the rate of efficacy of
CsCl in cancer therapy. The total 50 cancer cases
studied show an impressive 50% survival rate. This
confirms the work of Messiha reported in these proceedings
showing that the higher the dose it is, the more effective
it seems to be. The autopsy obtained from the
patient whose death was attributed to traumatic
fracture of the neck, indicated that cancer had been
initially further advanced resulting in bone destruction.
However, the absence of cancer after the massive CsCl dose
used in this case is demonstrable of the Cs-therapy.
It appears that both dosage, i.e., as much as 30 grams/day
and route of drug administration, i.e., nasogastric pathway,
might have contributed to the patients rapid
recovery. It should be noted, however, that CsCl dose
regimens should not exceed 20 to 40 grams due to side
effects, mainly nausea, and diarrhea. The authors
personal experience with CsCl after an acute dose of 40
grams CsCl indicate that extensive nausea and parethesia
around the mouth are the major side effects. This is
probably due to K depletion. The usual dose used in
the clinic ranges from 2 to 3 grams given by mouth 3 times
daily. At a later time, at which time there is no
indication of cancer presence, the CsCl dosage will be
reduced to a preventative dose between .5 and 1 gram a day.
The lymphoma case presented shows that CsCl efficiently
reduced massive enlargements of spleen and liver as well as
maximal ascites, causing an abdominal configuration of a
tight, hard hemisphere, to almost normalize after 3 months
of therapy. This period of time was required to
eliminate such a massive volume resulting in the reduction
of the body weight noted.
The clinical efficacy of CsCl high pH metabolic therapy is
best demonstrated by a recent case of primary liver cancer
(not included in the 50 cases reported in this study).
The patient was a 39 year old female teacher who was
terminal. She was brought on a stretcher on April 25,
1984 with a large liver tumor extending approximately 3 cm
below the umbilical level. The treatment was then
immediately instituted. This consisted of
administration of CsCl, Beta-carotene, Vitamin C, Zn, Se,
Mn, Cr, and K salts by the oral route in addition to a
concomitant massive IV doses of ascorbate, K, Mg, Zn, Cn,
Mn, Cr salts, B complex vitamins, folic acid, DMSO and
heparin. After 5 consecutive treatment regimens EDTA
was introduced to the therapy and the minerals present in
the solution were discontinued. On May 10, 1984, the
patient was discharged, returned home walking without
assistance and displaying a smile on her face. The
liver tumor had shrunk to 5 cm above the umbilicus.
The determination of alphafetoprotein (AFP), a specific
marker for liver cancer, rare embronal cancer and teratomas,
decreased from the unusually high value of 39,000 units,
compared to normal levels of 13 units, measured before
initiation of Cs-therapy, to 5000 units obtained on the last
day of treatment.
The mechanism of action of Cs in cancer has been little
studied. Both Cs+ and Rb+ can specifically enter the
cancer cells and embryonic cells, but not normal adult cells
has been demonstrated by Brewer. The cancer cells
contain high amounts of hydrogen ions rendering them acidic
and they also contain high Na+ levels than found in normal
cells. If Cs+ or Rb+ can enter the cancer cells then
the pH increases from as low as 5.5 to over pH 7.0. At
a pH of 7.6 the cancer cell division will stop, at a pH of
8.0 to 8.5 the lifespan of it is considerably shortened
(only hours). In one case, the author has observed the
shrinkage of metastases of breast cancer after one hour of
Cs-treatment. Two days later wrinkles of the skin
appeared where the tumor was present. In another case
of a colon cancer with massive metastasis, of massive
infiltration of the abdominal wall, liver and other tissues,
seemed to have been reduced within 24 hours and
continuing rapidly until the demise of the patient on the
14th day of the Cs-treatment.